醋酸头孢洛林酯(Ceftaroline Fosamil) - 药物靶点：PBPs_在研适应症：社区获得性肺炎，复杂的皮肤和软组织感染，社区获得性细菌性肺炎_专利_临床

Molecular determinants for Ceftaroline resistance in Clinical Isolates of Methicillin-Resistant Staphylococcus Aureus: A Cross sectional Pilot Study - NIL

开始日期2024-08-10

申办/合作机构-

PACTR202404502445612

/ RecruitingN/AIIT

Study of the efficacy of Ceftaroline in the management of pediatric severe sepsis and septic shock

开始日期2022-11-01

申办/合作机构-

NCT04198571

/ CompletedN/A

MULTINATIONAL Retrospective Chart Review Study to Assess the Characteristics, Treatment Outcomes and Resource Use Among Adult Patients Hospitalised for Community-Acquired Pneumonia (CAP) or Complicated Skin and Soft Tissue Infections (cSSTI) Treated With Zinforo (REGISTERED) (Ceftaroline Fosamil) in a Usual Care Setting

MULTINATIONAL Retrospective Chart Review Study to Assess the Characteristics, Treatment Outcomes and Resource Use Among Adult Patients Hospitalized for Community-Acquired Pneumonia (CAP) or Complicated Skin and Soft Tissue Infections (cSSTI) Treated with Zinforo® (ceftaroline fosamil) in a Usual Care Setting

开始日期2020-05-17

申办/合作机构

Pfizer Inc.

100 项与醋酸头孢洛林酯相关的临床结果

登录后查看更多信息

100 项与醋酸头孢洛林酯相关的转化医学

登录后查看更多信息

100 项与醋酸头孢洛林酯相关的专利（医药）

登录后查看更多信息

658

项与醋酸头孢洛林酯相关的文献（医药）

2026-02-04·ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Beyond mecA : a two-tiered mechanism and regulatory rewiring drive high-level ceftaroline resistance in clinical MRSA

Article

作者: Rosato, Roberto R. ; Dallaire, Margeurite ; Schaffer, Claire E. ; Vary, Calvin ; Karolak, Michele ; Rosato, Adriana E. ; Sassman, Melissa ; Gartner, Carlos

ABSTRACT:

High-level resistance to ceftaroline, a fifth-generation β-lactam critical for treating methicillin-resistant Staphylococcus aureus (MRSA), is an emerging threat to global health. While resistance is traditionally attributed to mecA -mediated expression of PBP2a, our study reveals a previously unrecognized mechanism. We show that high-level resistance to ceftaroline can arise independently of ceftaroline exposure through a collateral pathway triggered by carbapenems typically used to treat Gram-negative infections. Our findings reveal a two-tiered adaptive process. First, meropenem selects non-synonymous mutations in rpoB , a core transcriptional regulator, which primes resistance by reprogramming gene expression. These changes consistently co-occur with a key substitution in pbp1 (H499R), an essential protein for cell division, and specific mecA variants (Y446H, E447K) following ceftaroline exposure. Second, resistance is stabilized through regulatory and signaling adaptations, with elevated basal levels of the oxidative stress regulator Spx and its adaptor protein TrfA supporting the altered cellular state. Proteomic and biophysical studies revealed direct binding of TrfA to GdpP, the phosphodiesterase for cyclic-di-AMP, linking this regulatory circuit to elevated c-di-AMP levels and resistance maintenance. Our findings challenge the assumption that ceftaroline resistance is driven solely by PBP2a alterations and reveal how collateral resistance pathways can be activated by broad-spectrum antibiotic use. This study highlights the evolutionary capacity of MRSA to circumvent antibiotic pressure and underscores the need for improved antimicrobial stewardship.

2026-02-02·European Heart Journal-Case Reports

Successful resolution of methicillin-sensitive Staphylococcus aureus bacteraemia complicated by infective endocarditis in a patient with malignancy: a case report of effective combined intravenous nafcillin and ceftaroline therapy

Article

作者: Malik, Michelle ; Modrick, Joshua ; Matthews, Sajith ; Bilal, Mohammad Azfar

Abstract:

Background:

Infective endocarditis (IE) is a life-threatening complication of bacteraemia, with a high mortality rate especially in immunocompromised individuals. Cancer patients receiving chemotherapy through implanted venous access devices are at an elevated risk of healthcare-associated bacteraemia. While surgery is often indicated for persistent bacteraemia or embolic complications, it may be contraindicated in patients with significant comorbidities. Combination beta-lactam therapy, particularly with nafcillin and ceftaroline, has shown promise in clearing persistent methicillin-sensitive Staphylococcus aureus (MSSA) bacteraemia but has not been widely reported in oncology populations.

Case summary:

We present a case of 49-year-old woman with stage IA triple-negative breast cancer on chemotherapy via Port-a-Cath who was admitted to hospital with sepsis. Blood cultures revealed MSSA and echocardiography confirmed mitral valve vegetation, consistent with IE. Despite cefazolin therapy and port removal, bacteraemia persisted for 7 days. MRI and CT imaging revealed multiple embolic events, including cerebral infarcts and pulmonary emboli. Due to her poor surgical candidacy, combination therapy with IV nafcillin and ceftaroline was initiated. Fevers resolved and blood cultures cleared within 72 h. Ceftaroline was discontinued after 7 days, and nafcillin continued for 17 days before transitioning to cefazolin. She successfully completed 6 weeks of antibiotics with no recurrence of bacteraemia or IE.

Discussion:

This case demonstrates successful eradication of persistent MSSA IE using combination nafcillin and ceftaroline in a high-risk cancer patient for whom surgery was declined. It supports the potential role of dual beta-lactam therapy in managing complex IE when surgical options are limited.

2026-02-01·Expert Opinion on Drug Discovery

Advances in methicillin-resistant Staphylococcus aureus drug discovery: developments and challenges

Review

作者: Mylonakis, Eleftherios ; Vassilopoulos, Stephanos

INTRODUCTION:

Methicillin-resistant Staphylococcus aureus (MRSA) is a leading cause of severe infections with excess mortality. Progress with traditional antibiotics has been incremental, while resistance, persistence, tolerance, and biofilm formation continue to erode effectiveness. Parallel advances in small-molecule discovery, long-acting lipoglycopeptides, next-generation β-lactams, and non-traditional modalities such as bacteriophage lysins have renewed interest in expanding therapeutic options, though transition from promising preclinical signals to clinical benefit remains challenging.

AREAS COVERED:

A literature search was conducted using PubMed/MEDLINE, and Embase, for articles published from January 2010 through March 2025. This review synthesizes developments across: (i) agents in key clinical trials for invasive MRSA infection, emphasizing on trial designs, efficacy, and safety considerations; (ii) clinical study data with newer agents for MRSA skin infections and their potential application in invasive disease; (iii) preclinical pipelines including natural products, novel compounds, and other innovative antimicrobial strategies.

EXPERT OPINION:

Among investigated agents, ceftobiprole, ceftaroline, dalbavancin, and exebacase represent promising options for invasive MRSA infections. The pipeline is further strengthened by novel classes and antimicrobial peptides, which show anti-MRSA activity and a low risk for resistance in preclinical models. Continued multidisciplinary collaboration and robust clinical trial infrastructure are essential to translate these advances into improved patient outcomes.

10

项与醋酸头孢洛林酯相关的新闻（医药）

2026-01-30

·齐鲁制药集团

齐鲁出海新年开门红：双品同日发运美国，累计37个产品实现对美出口

1月30日，齐鲁制药两款制剂产品——注射用头孢洛林酯与醋酸加尼瑞克注射液，分别从齐鲁高新生产基地和生物医药产业园同步启程，正式发往美国市场。这是开年以来继盐酸尼卡地平注射液之后，齐鲁制药出口美国的第二与第三个产品，标志着齐鲁制药在“专利挑战抢占首仿”与“中美双报双批”领域双双再获突破性成果，不仅将公司对美国出口制剂产品总数提升至37个，更为新一年国际化征程奏响了激昂的序曲，实现了开门红。注射用头孢洛林酯是新型广谱第五代头孢菌素类抗生素，临床价值显著。通过与细菌细胞壁上的青霉素结合蛋白（PBPs）高亲和力结合，抑制细菌细胞壁合成而发挥杀菌作用。‌与前四代头孢菌素相比，头孢洛林酯具有耐药性较小、耐受性更好、副作用发生率较低的优点。此前，该产品在美国市场长期由原研企业独家供应，齐鲁制药自2014年即前瞻性启动美国ANDA申报，并于2021年9月获得美国FDA完全批准，通过发起专利挑战，最终以首仿产品较专利期提前五年上市，为当地抗感染治疗领域带来新的高质量选择。醋酸加尼瑞克是一种促性腺激素释放激素（GnRH）拮抗剂，在接受辅助生殖技术控制性卵巢刺激方案的妇女中，用于预防过早排卵。齐鲁制药的产品采用便捷的预灌封注射器包装，具有用药剂量准确、操作简便、污染风险低及便于储存运输等特点，能更好地满足临床需求。该产品是齐鲁制药首款实现对美出口的预灌封注射剂，也是公司“中美双报”战略的成功实践，实现了中美市场的同步供应。齐鲁制药于2023年向美国FDA提交上市申请获得受理，并于2024年在国内获批上市。此次对美发货，再次充分印证了齐鲁制药在同一产线、遵循全球统一质量体系生产的产品，能够同时满足中美两国市场的严苛标准，体现了公司在研发实力、产品质量、复杂制剂等方面的综合竞争力。两款产品虽然治疗领域与突破路径不同，但成功出海的根基均在于齐鲁制药与国际全面接轨的研发、生产与质量管理体系。一直以来，齐鲁制药始终坚持“共线生产，全球同质”的质量承诺，实施药品全生命周期质量管理。通过引进国际先进的生产技术和智能化装备，打造了世界一流的制剂智能制造平台，以高度的自动化、数字化和智能化水平，保障了产品品质的极致稳定与大规模生产效率。目前，齐鲁制药已经通过了全球所有主要法规市场的体系认证，持续拓展高端国际市场。截至目前，齐鲁制药的产品已稳定出口全球近110个国家和地区，每年惠及约15亿患者。多年来始终是国内唯一同时向欧盟、美国、英国、日本、澳大利亚、加拿大法规市场出口制剂的药企。未来，齐鲁制药将继续坚持创新与国际化双轮驱动战略，聚焦临床需求，依托强大的研发体系和智能制造平台，稳步推进国际化布局，推动更多高品质、可及的药品服务全球患者，践行“用科技表达我们的爱”的初心，朝着“成为有全球影响力的世界级制药企业”的愿景坚实迈进。供稿：齐鲁制药有限公司点击下方关键词获取更多资讯 ↓↓ 李燕总裁 | 全国人大代表中国医药百强 | 伊鲁阿克 | 患者招募雷珠单抗 | 艾托组合抗体 | 帕妥尤单抗董事长的二十万个蛋糕 | 社会责任企业

2023-09-16

·药融圈

01药融圈介绍药融圈围绕我国生物医药产业链，针对生物医药大数据、技术和资本投资，挖掘海量资源。为医药行业提供CRO/CDMO/CMO对接、研发技术、企业股权、批文、融资合作等多种项目的供需合作信息，促进我国生物医药产业健康发展，完善产业链，共同面对全球合作和竞争。02项目合作01CDMO/CMO需求💥【急需】化药喷雾剂寻找CMO合作包材为玻瓶或铝罐,轧盖或冲盖,防爆,能满足铝罐轧盖,防爆多剂量鼻喷剂cmo塑料瓶10ml/瓶，0.14mg/喷无菌原料药CDMO平台寻求项目合作批量小（0.5kg～30kg）&粒径2～10um，高度自动化，cGMP，中美双报，B&C洁净区！激素类口服液CMO生产线小水针CMO能生产含有乙醇的小水针生产线，2ml玻璃安瓿瓶，含有5%(v/v)的乙醇，终端灭菌。小分子鼻喷剂非激素，委托生产对接联系人：Amanda 13306586060Coco 15706844213Lucy 1595867500102新药/改良新药转让项目司美格鲁肽片剂小试研究过程中，目前原研公司诺和诺德在国内同时开展II型糖尿病和减重两个领域的三期临床；目前具备司美格鲁肽的原料药来源；MAH持证转让山梨醇甘露醇冲洗剂、羧甲司坦口服溶液、洛索洛芬钠口服溶液、依巴斯汀口服溶液、注射用尼可地尔、盐酸屈他维林注射液等产品；某化疗止吐药物注射混悬液（130mg）计划2023Q3 申报IND某抗血小板药物缓释片（60mg，90mg）批准临床某抗精神分裂症药物口溶膜（1mg，2mg）批准临床对接联系人：Amanda 13306586060Coco 15706844213Lucy 1595867500103仿制药转让项目来特莫韦原料药+注射液+片剂磷酸奥司他韦胶囊275mg,完成中试，随时可注册批琥珀酸索利那新片5mg完成中试，准备注册批二甲双胍维格列汀片850mg:50mg、1000mg:50mg降糖预BE通过马来酸奈拉替尼片40mg - 即将获批；原料药&制剂糠酸氟替卡松鼻用喷雾剂（文适）中试阶段阿瑞匹坦胶囊（80mg；125mg）BE 进行中非诺贝特胆碱缓释胶囊包材为玻瓶或铝罐，轧盖或冲盖，防爆，能满足铝罐轧项目转让罗沙司他胶囊包材为玻瓶或铝罐，轧盖或冲盖，防爆，能满足铝罐轧替米沙坦氨氯地平片规格：80mg:5mg 完成验证批，完成预BE地屈孕酮片 10mg 原料药&制剂联合开发，中试阶段己酮可可碱注射液(5ml:100mg） 3 类 ANDA 中盐酸阿考替胺片及原料临床批件他达拉非片10、20mg 临床批件托普司他片及原料片剂：20、40、80mg 临床批件注射用头孢罗膦无菌分装：0.4、0.6g 临床批件尼达尼布软胶囊及原料软胶囊：100、150mg 临床批件复方去氧肾上腺素冲洗液安瓿：4ml 临床批件醋酸乌利司他片及原料片剂：30mg、5mg 临床批件对接联系人：Amanda 13306586060Coco 15706844213Lucy 1595867500104标的转让收购/入股原料药生产工厂场地要求：1、有GMP资质、最好已取得药品生产许可证；2、能做氢化反应，有高压釜；3、有精馏设备；4、有乙醚、氯仿、盐酸等易制毒、易制爆的资质；标的转让占地60亩，5个甲类标准车间、500平加氢车间、位于精细化工园区，产值1.2亿工厂资质：危险品许可证、排污许可证、2/3类非易制毒化学品生产备案证明、ISO 自有产品线：吡啶和烟酸系列标的转让占地84.33亩，一期2个2700平方米的生产车间，720平方米甲类库，2400平方米丙类库，污水处理能力200吨/天；反应釜共有80多台套，1000L~5000反应釜70余台套、离心机16台、干燥设备17台；中试设备：100L~300L搪玻璃釜5台；加氢设备 1000L釜1台、3000L釜2台、316L不锈钢材质；标的求购寻求原料药中间体车间，区域要求山东境内对接联系人：Amanda 13306586060Coco 15706844213Lucy 1595867500105批文转让求购罗沙司他批文，胶囊或者片剂抗肿瘤小分子靶向或细胞毒药物批文，剂型不限呼吸系统吸入制剂；泌尿系统PED5抑制剂心脑血管、呼吸、肿瘤、神经精神及代谢领域已上市或即将上市的产品批文，剂型要求口服类对接联系人：Amanda 13306586060Coco 15706844213Lucy 15958675001更多供需详情扫码左边二维码一键填写

临床3期申请上市临床申请CSCO会议临床1期

2023-07-24

·GlobeNewswire-Health Care

AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti

These new appointments bring extensive US and international experience in company leadership and development of anti-infectives from R&D to commercialization.Lyon - France, July 24, 2023 (GLOBE NEWSWIRE) -- AUROBAC THERAPEUTICS WELCOMES TWO NEW INDEPENDENT MEMBERS TO ITS BOARD: MANOS PERROS, AS CHAIRMAN, AND MARCO TAGLIETTI Dr Manos Perros and Dr Marco Taglietti are appointed new Independent Members of the Board of AUROBAC THERAPEUTICSDr Perros becomes Chairman of the Board These new appointments bring extensive US and international experience in company leadership and development of anti-infectives from R&D to commercialization Lyon (France), Thursday July 24, 2023 AUROBAC THERAPEUTICS SAS, a biopharmaceutical company developing the next generation of products to fight antimicrobial resistance (AMR), is delighted to announce the appointment of Manos Perros, Ph.D., as the new Chairman of the Board and welcomes Marco Taglietti, M.D., as an Independent Board Member. Their unique expertise in bringing antimicrobials and antifungals to market, as well as their extensive background in the pharmaceutical and biotech industries, will contribute greatly to AUROBAC's strategic decision-making and overall growth. "We are thrilled to welcome Dr Manos Perros as our new Chairman of the Board and Dr Marco Taglietti as an Independent Member” said Frank Kalkbrenner, former Chairman of the Board, representing Boehringer Ingelheim, main shareholder of AUROBAC THERAPEUTICS. "As former CEOs of biotech companies which have successfully developed anti-infectives, their wealth of experience and strategic vision will be instrumental in guiding AUROBAC's future endeavors. We believe that their appointment will further strengthen our Board and enhance our ability to pursue our mission to develop and bring to market innovative products to fight AMR." Dr Manos Perros is a distinguished pharmaceutical and biotech executive with an impressive track record of more than 25 years in life sciences research and development. Prior to his appointment at AUROBAC, Dr Perros was Chief Executive Officer of Entasis Therapeutics, where he played a pivotal role in establishing the company as a prominent player in the industry during his seven-year tenure, resulting in the acquisition of the company by Innoviva in 2022 and the recent FDA approval of Xacduro, the first targeted treatment for Acinetobacter baumannii pneumonia. Dr. Perros has successfully led numerous companies through various stages of growth and development, earning him a reputation as a visionary leader in the industry. His strategic insights and wealth of knowledge in anti-infective drug development will undoubtedly play a pivotal role in steering AUROBAC THERAPEUTICS towards achieving its goals. Dr Perros, expressed his enthusiasm for the role, saying, "I am honored to take on the role of Chairman of AUROBAC’s Board and to help shape the future of AUROBAC while contributing to the fight against antimicrobial resistance. AUROBAC's mission aligns perfectly with my passion for developing innovative therapies and addressing critical healthcare challenges. Together with the talented team at AUROBAC, we will leverage the power of precision medicine and advanced diagnostics to make a significant impact in the battle against AMR." Dr Marco Taglietti is a respected figure in the biotechnology sector, having notably served as the President and Chief Executive Officer of Scynexis, Inc (Nasdaq: SCYX) for 8 years, where he successfully achieved two approvals by FDA for Brexafemme (ibrexafungerp), a novel, first-in-class medicine to treat fungal infection, followed by an exclusive agreement with GSK to commercialize and further develop Brexafemme. During his career, he completed several successful rounds of financing and company restructuring, managed groups up to 1,600 employees in global organizations and R&D budgets up to $950 million/year and contributed to the approval of over 35 products globally, including several anti-infectives such as Avycaz (ceftazidime and avibactam), Teflaro (ceftaroline) and Brexafemme (ibrexafungerp). His extensive experience in developing and bringing to market innovative medicines perfectly fits with AUROBAC's mission. "I am excited to be part of AUROBAC's Board and contribute to its efforts in developing novel solutions to fight antimicrobial resistance." said Dr Taglietti. "Together, we have a unique opportunity to make a real difference in patient care by focusing on precision medicines associated with advanced diagnostics." AUROBAC THERAPEUTICS’ Board now comprises Frank Kalkbrenner and Karl Penz, representing Boehringer Ingelheim, Philippe Archinard, representing bioMérieux, Antonio Felici, representing Evotec SE, Marco Taglietti as Independent Member and Manos Perros as Independent Member and Chairman. With this Board working in collaboration with AUROBAC’s leadership team, AUROBAC THERAPEUTICS is well-positioned to drive innovation, improve patient outcomes, and address the critical global health challenge of antibiotic resistance. About AUROBAC THERAPEUTICS: AUROBAC THERAPEUTICS is a biopharmaceutical company founded in 2022 by three highly renowned life sciences innovation companies, Boehringer Ingelheim, Evotec and bioMérieux, to develop the next generation of precision medicines addressing the medical needs associated with the development of antimicrobial resistance and infectious diseases. The company is building a pipeline of drug candidates for hospitalized patients, associated with rapid diagnostics to identify pathogens and their resistance mechanisms. This 40 million euros-funded joint-venture plans to cover the entire value chain of projects from R&D, including clinical development, to registration and commercialization. Contacts: Florence Séjourné, CEOaurobac-tx.com Attachment 2023.07.24 ATX PR Board Appointments vf

上市批准高管变更并购

100 项与醋酸头孢洛林酯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08884	醋酸头孢洛林酯	J01DI02	DB06590

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
社区获得性肺炎	欧盟	Pfizer Manufacturing Ireland Unlimited Co.	2012-08-22
社区获得性肺炎	冰岛	Pfizer Manufacturing Ireland Unlimited Co.	2012-08-22
社区获得性肺炎	列支敦士登	Pfizer Manufacturing Ireland Unlimited Co.	2012-08-22
社区获得性肺炎	挪威	Pfizer Manufacturing Ireland Unlimited Co.	2012-08-22
复杂的皮肤和软组织感染	欧盟	Pfizer Manufacturing Ireland Unlimited Co.	2012-08-22
复杂的皮肤和软组织感染	冰岛	Pfizer Manufacturing Ireland Unlimited Co.	2012-08-22
复杂的皮肤和软组织感染	列支敦士登	Pfizer Manufacturing Ireland Unlimited Co.	2012-08-22
复杂的皮肤和软组织感染	挪威	Pfizer Manufacturing Ireland Unlimited Co.	2012-08-22
社区获得性细菌性肺炎	美国	AbbVie, Inc.	2010-10-29
皮肤和皮肤结构感染	美国	AbbVie, Inc.	2010-10-29

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
细菌性肺炎	申请上市	中国	Pfizer Inc.	2017-10-31
细菌性皮肤疾病	申请上市	中国	Pfizer Inc.	2017-10-31
软组织感染	临床3期	美国	Facta Farmaceutici SpA	2012-05-21
软组织感染	临床3期	美国	阿斯利康制药有限公司	2012-05-21
软组织感染	临床3期	阿根廷	Facta Farmaceutici SpA	2012-05-21
软组织感染	临床3期	阿根廷	阿斯利康制药有限公司	2012-05-21
软组织感染	临床3期	奥地利	Facta Farmaceutici SpA	2012-05-21
软组织感染	临床3期	奥地利	阿斯利康制药有限公司	2012-05-21
软组织感染	临床3期	比利时	Facta Farmaceutici SpA	2012-05-21
软组织感染	临床3期	比利时	阿斯利康制药有限公司	2012-05-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04198571 (Pubmed)	N/A	复杂的皮肤和软组织感染	132	Ceftaroline fosamil	醖艱鏇糧壓壓繭壓積鬱(蓋鏇築憲鏇壓築醖廠遞) = 齋觸憲鹹獵膚積鬱顧鏇鑰醖餘築窪觸淵顧襯獵 (鹹鏇遞顧範簾繭膚觸壓 ) 更多	积极	2024-07-01
NCT01734694 (STOP-NT, CTgov)	临床4期	感染性关节炎 \| 心内膜炎 \| 骨髓炎 ... 更多	100	Vancomycin (Vancomycin)	簾膚鹽繭膚繭繭製艱願 = 餘壓壓築衊鬱膚餘淵衊艱積鬱壓鹹積網遞簾顧 (鑰網壓餘網襯憲積鑰願, 鑰製選齋淵窪壓廠構觸 ~ 膚糧餘淵齋夢選積鏇艱) 更多	-	2023-05-03
				Ceftaroline+Linezolid+Daptomycin (Comparator)	簾膚鹽繭膚繭繭製艱願 = 鏇觸艱遞簾築淵醖鹽蓋艱積鬱壓鹹積網遞簾顧 (鑰網壓餘網襯憲積鑰願, 築鏇蓋構窪齋積簾壓壓 ~ 觸齋範鬱鹹鏇餘壓網鹽) 更多
NCT01371838 (ASIA CAP, Pubmed \| Infect Drug Resist)	临床3期	社区获得性肺炎	302	Ceftaroline fosamil 600 mg	鑰淵鹹積窪鹽醖網選獵(襯範鏇觸繭膚鏇襯積襯) = 鑰衊鏇願夢網獵鹽構夢艱簾窪範獵襯壓鏇衊繭 (繭繭鹽壓憲壓鹽膚築選, 2.5 ~ 27.6)	积极	2022-01-01
				Ceftriaxone 2 g	鑰淵鹹積窪鹽醖網選獵(襯範鏇觸繭膚鏇襯積襯) = 襯積構鬱範蓋構壓製繭艱簾窪範獵襯壓鏇衊繭 (繭繭鹽壓憲壓鹽膚築選 )
NCT00423657 \| NCT01499277 \| NCT00424190 \| NCT00509106 \| NCT01371838 \| NCT00621504 (CANVAS 1 \| CANVAS 2 \| COVERS, Pubmed \| J Glob Antimicrob Resist) 人工标引	临床3期	菌血症	1,976	Ceftaroline	獵構繭顧衊觸網齋衊襯(顧鏇獵構膚襯鏇網艱襯) = 壓餘淵壓製選鹹築積醖製構窪窪淵鹽齋範餘夢 (獵膚築糧簾廠膚繭構選 ) 更多	积极	2021-12-16
				comparator	獵構繭顧衊觸網齋衊襯(顧鏇獵構膚襯鏇網艱襯) = 構艱襯壓選鹹鏇獵糧衊製構窪窪淵鹽齋範餘夢 (獵膚築糧簾廠膚繭構選 ) 更多
NCT00423657 \| NCT01499277 \| NCT00424190 (Pubmed \| Infect Dis Ther)	临床3期	复杂的皮肤和软组织感染	1,808	Ceftaroline fosamil	艱製鏇廠鏇蓋構艱壓鹽(艱鹹製鑰簾選鏇鹽淵獵) = 衊廠觸憲餘顧襯鑰觸窪鏇餘網壓餘鏇膚鑰窪壓 (鏇觸觸構壓鹹餘選憲憲 )	-	2021-11-06
				Vancomycin plus aztreonam	艱製鏇廠鏇蓋構艱壓鹽(艱鹹製鑰簾選鏇鹽淵獵) = 鬱積鏇構鏇齋遞糧淵醖鏇餘網壓餘鏇膚鑰窪壓 (鏇觸觸構壓鹹餘選憲憲 )
NCT02335905 (CTgov)	临床1/2期	骨感染 \| 金黄色葡萄球菌感染 \| 骨髓炎	11	Ceftaroline Fosamil	餘餘網蓋網壓積構遞遞 = 簾積製憲壓蓋壓鏇積網顧窪鏇膚廠夢範選廠鏇 (鏇顧憲艱遞鑰衊顧鑰遞, 構選齋獵夢醖繭夢築構 ~ 廠製糧簾蓋築築艱鹹觸) 更多	-	2021-11-02
NCT01499277 (COVERS, Pubmed \| Infect Dis Ther)	临床3期	复杂的皮肤和软组织感染	761	Ceftaroline fosamil	艱範鑰壓壓鹹膚膚餘蓋(醖簾齋齋餘獵鹽築膚餘) = 築憲鹽鹹鹽鹹積膚顧蓋鏇鬱憲壓齋壓壓夢獵範 (齋範糧選齋蓋鹹衊築壓 )	-	2020-06-30
				Vancomycin plus aztreonam	艱範鑰壓壓鹹膚膚餘蓋(醖簾齋齋餘獵鹽築膚餘) = 窪鹹觸憲齋簾築鑰繭鏇鏇鬱憲壓齋壓壓夢獵範 (齋範糧選齋蓋鹹衊築壓 )
NCT01458743 \| NCT01371838 (Pubmed \| Clin Pharmacol Drug Dev)	临床3期	社区获得性肺炎	848	Ceftaroline Fosamil (Asian patients with CAP)	鏇觸遞製鹽淵壓構襯網(窪鹽鏇壓簾顧遞醖齋淵) = 糧憲願築醖網餘艱齋製襯選醖構餘壓鹹窪廠鏇 (製艱繭繭廠醖願衊衊鹹 )	-	2019-07-01
NCT00423657 \| NCT01499277 \| NCT00424190 (Pubmed \| Int J Antimicrob Agents)	N/A	皮肤和皮肤结构感染	-	Ceftaroline fosamil 600 mg q12h	襯鑰鏇觸壓鹽糧淵鹽壓(糧鹽餘衊鏇鑰鹹齋簾鬱) = 遞壓顧鹹膚製艱艱積網顧衊餘顧簾繭艱醖觸餘 (糧繭築構鏇觸築蓋願艱 )	-	2019-06-01
				Ceftaroline fosamil 600 mg q8h	襯鑰鏇觸壓鹽糧淵鹽壓(糧鹽餘衊鏇鑰鹹齋簾鬱) = 廠壓蓋襯鹹糧壓衊鑰淵顧衊餘顧簾繭艱醖觸餘 (糧繭築構鏇觸築蓋願艱 )
NCT02806882 (Pubmed \| J Antimicrob Chemother)	临床1期	-	9	Ceftaroline 600 mg	襯製觸糧艱積襯餘鹽廠(構鏇鏇餘鏇齋艱製獵醖) = 願膚齋壓遞鏇醖夢積築鹽蓋窪選蓋範積蓋襯獵 (獵淵憲衊積餘蓋蓋鹽夢 )	-	2019-03-01